Successful endovascular aneurysm repair (EVAR) requires a secure fixation of the proximal end of the aortic endograft 1 to prevent stent-graft migration and proximal endoleak. 2, 3 Suprarenal endograft fixation has been proposed to overcome the problem of an unfavorable or suboptimal proximal neck o increase the number of patients eligible for EVAR. 4 However, concern persists regarding the long-term effect on renal function when struts of the uncovered stent cross the renal arteries ostia. 5 Many authors have reported their experience with various follow-up periods without showing any significant impact of suprarenal endograft fixation on renal function. [6] [7] [8] [9] We reviewed our experience with suprarenal endograft fixation compared with infrarenal endograft fixation to determine whether there is a difference in long-term renal function.
METHODS
Prospectively collected data in computerized databases of 277 patients treated by EVAR for nonruptured infrarenal aortoiliac aneurysms (Ͼ5 cm in diameter, between 4 and 5 cm in diameter with a documented increase in diameter of 0.5 cm in the past 6 months, twice the diameter of the infrarenal neck, or saccular, with infrarenal neck length of at least 1.5 cm) in two institutions between January 2000 and June 2003 were retrospectively reviewed. An endograft with infrarenal fixation (Medtronic AneuRx) was used to treat 135 patients (Group IF); 127 patients were treated in Stanford University Hospital, Stanford, Calif and eight patients were treated in HenriMondor University Hospital, Creteil, France. None of these patients required dialysis because of preoperative chronic renal failure. Two endografts with suprarenal fixation were used in 142 patients; 108 patients were treated with the Cook Zenith endograft in Henri-Mondor University Hospital, and 34 patients were treated with the Medtronic Talent stent graft at Stanford University Hospital. Of these 142 patients, five patients who required dialysis because of preoperative chronic renal failure were excluded from further analysis. Of the remaining 137 patients (group SF), 106 patients were treated with Cook Zenith and 31 patients were treated with Medtronic Talent. Baseline patient demographic data, preoperative aortic aneurysm size, and risk factors as defined by the Society for Vascular Surgery/American Association for Vascular Surgery reporting standard, 10 were obtained for all patients. Renal function was evaluated by calculating the creatinine clearance (CrCl) using the Cockroft et al formula 11 : CrCl ϭ (140 Ϫ age) (wt)/(72 ϫ Scr), age in years, wt is absolute body weight in kilograms, Scr is serum creatinine in mg/100 mL.
Changes in renal function were evaluated by comparing the preoperative and the latest available postoperative CrCl. The observation period was defined as the interval from surgery to the most recent follow-up examination.
Only patients with a Ն20% decrease in CrCl were considered to have impaired renal function. 8 Both institutions used the same methods for pretreating patients with renal insufficiency. The protocol used was based on intravenous hydration for 48 hours preoperatively, and for patients with a creatinine clearance Ͻ40 mL/min, an antioxidant supplementation was added 2 days preoperatively. A similar postoperative surveillance with contrast computed tomography (CT) scan (at 1, 3, 6, and 12 months and annually thereafter) was performed for all patients in both institutions.
Statistical analyses were performed using the 2 test and Student's t test. Multiple logistic regression analysis was used to determine the factors independently associated with postoperative renal impairment. Independent factors that were included in multiple logistic regression modeling were the type of fixation, age, sex, diameter of the abdominal aortic aneurysm (AAA), preoperative risk factors, preoperative CrCl, and follow-up period. A Kaplan-Meier life-table analysis of survival free from renal impairment, using Ն20% decrease in CrCl as the event, was performed in both groups, with a log-rank (Mantel-Cox) test to compare them. Differences were deemed significant at P Ͻ .05.
RESULTS
There were no significant differences in patient age, sex, aneurysm size, preoperative risk factors, or baseline CrCl (IF: 69.3 mL/min, SF: 71.7 mL/min, P ϭ .4) between the two groups ( Table I ). The amount of intraoperative contrast media and the number of postoperative contrastenhanced CT scans were similar in both groups (Table II) . Follow-up time was 12.2 months in both groups (range, 1 to 46 months), with similar variance. CrCl decreased significantly during the follow-up period in both groups (IF: 69.3 mL/min to 61.7 mL/min, P Ͻ .01; SF: 71.7 mL/ min to 64.9 mL/min, P Ͻ .03). Postoperative CrCl (IF: 61.7 mL/min, SF: 64.9 mL/min, P ϭ .3), and rate of CrCl decrease during the follow-up period (IF: Ϫ10.9 %, SF: Ϫ9.5 %, P ϭ .2) were comparable between the two groups (Table III) .
The number of patients with a Ͼ20% decrease in CrCl was not different between the two groups (IF: n ϭ 35 [25.9%] , SF: n ϭ 41 [29.9%], P ϭ .46). The magnitude of decrease in CrCl in patients with renal impairment was significantly greater in patients treated with suprarenal fixation endografts (SF: Ϫ39%) compared with those treated with infrarenal endografts (IF: Ϫ31%, P ϭ .005). This greater degree of renal impairment was not due to identifiable differences in preoperative risk factors, age, sex, AAA size, baseline CrCl, or follow-up length (Table IV) .
The multiple logistic regression modeling showed that site of fixation, age, sex, AAA size, preoperative risk factors, and the amount of intra-or postoperative contrast media were not associated with renal impairment, but the preoperative CrCl and the length of follow-up were independently associated with renal impairment (Table V) .
Kaplan-Meier life-table analysis of survival free from renal impairment showed no difference between the two groups. Mean survival was 31.1 months in group IF and 29.2 months in group SF (P ϭ .48 with log-rank test) (Fig 1) . No patient in this series required dialysis.
DISCUSSION
This study analyzed two large series of patients treated with EVAR in two separate institutions during the same period of time. Both institutions routinely treated patients with infrarenal aneurysms using EVAR with the same range of indications. This may explain why both series are very comparable in terms of number of patients, age, sex, aneurysm size, preoperative risk factors, baseline CrCl, and follow-up period. All patients treated with the three most commonly implanted commercial endograft devices were reviewed at both institutions. The AneuRx stent graft is now the most commonly implanted infrarenal device. 12 The Zenith and the Talent devices represent the most commonly implanted endografts with suprarenal fixation. 13, 14 These two endografts have similar systems of bare metal transrenal fixation, with differences in uncovered stent configuration regarding length and number of crowns and barbs. It should be noted that stents used to support endografts vary in construction, and their configuration may influence their ability to affect renal function. 15 At Stanford, Talent endografts were used more likely for patients with shorter necks, but there were no strict anatomic selection criteria. At Henri-Mondor, the Zenith endograft was the only implanted device during this period.
Long-term CrCl was used as the main end point to define the evolution of renal function. Many authors have suggested that renal function can be adequately assessed only with measurements of CrCl. 16 More sensitive tests can be applied to determine the true effect of EVAR on renal function, such as measurement of glomerular filtration rate by renal scintigraphy, 17 but such tests may not be practical as routine investigations in large series of patients. 18 Shortterm CrCl may be influenced by many factors during the perioperative period such as the duration of the procedure, anesthetic agents, nephrotoxic contrast media, and thus may not be used as reliable evidence of definite renal impairment. 19 For this reason, we recorded the latest postoperative CrCl at least 1 month after the procedure. We noted an overall decrease in long-term CrCl of 10.2% (P ϭ .0005), which is comparable with other series in the literature. We found no significant difference between patients treated with infrarenal compared with those treated with suprarenal fixation endovascular devices (10.9% vs 9.5%, P ϭ .2). [20] [21] [22] The long-term decline in renal function after EVAR was comparable with the decline after open repair of aortic aneurysms reported by Greenberg et al. 23 In our experience, long-term CrCl decreases of 6.4% after open surgery. Only part of the decrease can be related to the effect of age on CrCl, as Tiao et al 24 have shown that after the of age 75 years, patients lose about 2% of CrCl per year. Regardless the type of endograft used, there is a significant decrease overtime in CrCl after aortic endografting that cannot be only explained by the effect of age on renal function.
We considered a Ͻ20% decrease in CrCl to be related to physiologic daily variations without clinical consequences. The choice of a Ն20% decrease in CrCl after EVAR as a definition of postoperative renal impairment appears clinically relevant. 8, 25, 26 The number of patients with a Ͼ20% decrease in CrCl is the second end point of this study. We found no difference between Supra and Infra renal endografts (29.9% vs 25.9%, P ϭ .46) and no association between the fixation site and renal impairment in a multiple logistic regression modeling. These results are confirmed by a Kaplan-Meier life-table analysis of survival free from renal impairment (Fig 1) . Suprarenal fixation does not seem to increase the number of patients with renal impairment after aortic endografting.
There were no identifiable differences in preoperative risk factors, age, sex, or baseline CrCl in this subgroup (Table III) . However, our study showed that a higher preoperative CrCl appears to be associated with a greater magnitude of postoperative renal dysfunction, 9 suggesting that patients with poorer preoperative renal function were less likely to have worsening postoperative renal function (Table IV) . Although we did not show any statistical significance, this could be explained by the efficiency of perioperative protocols of hydration and the minimal use of contrast media during and after the procedure, with limitation of postoperative use of contrast in imaging examinations, in patients with preoperative renal dysfunction. 27 These results suggest that when physicians are aware of preoperative renal failure, they take measures to protect the patient from renal function worsening. Such strategies should be considered for all patients undergoing aortic aneurysm repair, which may reduce the effect of aortic stent grafting on renal function. However, this might still be difficult to apply to patients included in clinical trials in which they are subjected to a more rigorous surveillance protocol including frequent contrast-enhanced CT scans.
The magnitude of decrease of CrCl in patients who experienced significant renal impairment was significantly greater for patients treated with suprarenal fixation endografts (SF: Ϫ39%) compared with those treated with infrarenal endografts (IF: Ϫ31%, P ϭ .005). These results do not take into account the inherent inaccuracy of the Cockcroft formula (correlation coefficient ϭ .83). 11 In the group of patients who had Ͼ20% decrease in CrCl, the infrarenal fixation group had a lower mean age than the suprarenal fixation group, and this difference may have also affected the calculations of the mean CrCl for each group. Patients who experienced the greatest postoperative renal impairment may have had renal infarctions, but the exact cause of decline in renal function was not clearly defined in most patients. However, significant renal parenchymal tissue loss 28 or renal artery stenosis can occur without a significant effect on CrCl. 7, 29, 30 The exclusion of accessory renal arteries secondary to endograft deployment does not appear to be responsible for renal function impairment if the parenchyma loss is Ͻ25%. 31 In previous studies, [32] [33] [34] the small number of diagnosed renal infarctions that occurred was clinically benign. No patient in these series required dialysis or had any symptoms of renal dysfunction. One limitation of our study is that we were unable to accurately report on postoperative changes in blood pressure (renovascular hypertension) that might have resulted from suprarenal stenting. Two series in the literature reported no significant change in average recorded blood pressure at 6 and 12 months after suprarenal fixation. 3, 35 We believe that patients with significant renal impairment should be followed more closely with regular CrCl measurements; adapted imaging such as noncontrast-enhanced CT scans, infrarenal color duplex examinations, 19 and magnetic resonance angiography; and screening of renovascular hypertension. Close follow-up will help to detect possible late renal dysfunction and to prevent its clinical symptoms such as renovascular hypertension.
In conclusion, regardless the type of endograft used, there is approximately a 10% decrease in CrCl in the first year after EVAR. Suprarenal fixation does not seem to increase the likelihood of postoperative renal impairment. Decline in renal function over time after EVAR is probably due to multiple factors, and measures known to be effective in protecting kidneys should be considered for patients treated with EVAR. Long-term follow-up with measurement of CrCl, along with renal imaging and regular blood pressure measurements, should be performed to detect possible late renal dysfunction. Prospective studies comparing suprarenal versus infrarenal fixation are needed to confirm those results.
